

Daniele Santini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6758706/daniele-santini-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

317 papers	8,457 citations	45 h-index	83 g-index
334 ext. papers	9,978 ext. citations	5 avg, IF	5.45 L-index

#	Paper	IF	Citations
317	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 9	22.4	0
316	First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 439-439	2.2	
315	Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors.. <i>Journal of Bone Oncology</i> , 2022 , 34, 100422	4.5	0
314	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy.. <i>Journal of Chemotherapy</i> , 2022 , 1-7	2.3	
313	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021 , 107, 542-549	1.7	1
312	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-7	3.5	2
311	Bone metastases from urothelial carcinoma. The dark side of the moon.. <i>Journal of Bone Oncology</i> , 2021 , 31, 100405	4.5	0
310	Bone Health in Cancer Patients. <i>UNIPA Springer Series</i> , 2021 , 365-380	0.1	
309	Metastatic Renal Cell Carcinoma Classified as Good Risk: The Easiest Choice Has Become the Hardest. <i>Chemotherapy</i> , 2021 , 66, 196-198	3.2	1
308	S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. <i>Chemotherapy</i> , 2021 , 66, 161-168	3.2	
307	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 2021 , 9,		20
306	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021 , 11, 657639	5.3	7
305	Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. <i>Thoracic Cancer</i> , 2021 , 12, 1791-1792	3.2	
304	A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5052-5052	2.2	
303	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021 , 11, 682449	5.3	3
302	The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC. <i>Current Oncology</i> , 2021 , 28, 2097-2106	2.8	1
301	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021 , 19, 270	8.5	3

300	Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e137-e138	4.9	
299	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021 , 124, 183-190	8.7	5
298	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021 , 142, 18-28	7.5	27
297	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. <i>Translational Lung Cancer Research</i> , 2021 , 10, 80-92	4.4	3
296	Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 320-320	2.2	0
295	Osteonecrosis of the jaw in metastatic renal cell carcinoma (mRCC) patients treated with zoledronic acid and denosumab: An observational retrospective multicenter trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 299-299	2.2	
294	Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. <i>Journal of Bone Oncology</i> , 2021 , 26, 100341	4.5	0
293	Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 319-319	2.2	
292	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154	7.5	6
291	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021 , 19, 328	8.5	0
290	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
289	Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma. <i>Biology</i> , 2021 , 10,	4.9	1
288	ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more. <i>International Immunopharmacology</i> , 2021 , 98, 107673	5.8	0
287	Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. <i>Oncogene</i> , 2021 , 40, 1284-1299	9.2	16
286	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 121-125	2.7	5
285	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
284	Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms.. <i>Frontiers in Oncology</i> , 2021 , 11, 789885	5.3	0
283	Steroid-refractory immune related hepatitis may hide viral re-activation. <i>Future Science OA</i> , 2020 , 6, FSO614	6.14	1

282	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 2020 , 8,		47
281	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	2
280	Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer. <i>European Thyroid Journal</i> , 2020 , 9, 157-161	4.2	3
279	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020 , 12,	6.6	10
278	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. <i>ESMO Open</i> , 2020 , 5,	6	14
277	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
276	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 95	12.8	69
275	Facing SARS-CoV-2 outbreak in immunotherapy era. <i>Future Oncology</i> , 2020 , 16, 1475-1485	3.6	8
274	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020 , 5,	6	5
273	Current and Emerging Biomarkers Predicting Bone Metastasis Development. <i>Frontiers in Oncology</i> , 2020 , 10, 789	5.3	3
272	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
271	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020 , 120, 17-24	7.5	41
270	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
269	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 319-326	5.4	8
268	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020 , 37, 1145-1155	4.1	52
267	Dynamic changes of Receptor activator of nuclear factor- κ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. <i>Scientific Reports</i> , 2020 , 10, 1288	4.9	12
266	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>OncoImmunology</i> , 2020 , 9, 1710389	7.2	6
265	Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e105-e106	8.9	10

264	Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4016-4016	2.2	4
263	Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4077-4077	2.2	1
262	Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 691-691	2.2	1
261	Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 751-751	2.2	3
260	Prognostic and predictive factors in pancreatic cancer. <i>Oncotarget</i> , 2020 , 11, 924-941	3.3	24
259	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS596-TPS596	2.2	
258	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 752-752	2.2	1
257	Efficacy of third-line anti-EGFR-based treatment (tx) versus (vs) Regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4082-4082	2.2	
256	Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O):A real-world study on behalf of Meet-URO group (MeetUro-7b).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17088-e17088	2.2	
255	Breakthrough cancer pain clinical features and differential opioids response: A machine learning approach in 4,016 cancer patients of IOPS-MS study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e24150-e24150	2.2	1
254	Role of glyoxalase-1 in trabectedin-resistant myxoid liposarcoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e23566-e23566	2.2	
253	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020 , 134, 19-28	7.5	21
252	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 493-501	4.9	5
251	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
250	Recent Advances in Desmoid Tumor Therapy. <i>Cancers</i> , 2020 , 12,	6.6	3
249	The emerging role of PARP inhibitors in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 715-726	3.5	2
248	Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine Carcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. <i>BMJ Open</i> , 2020 , 10, e034393	3	8
247	Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 1325	5.3	6

246	Brief letter of a doctor to his psychologist in the COVID-19 outbreak era. <i>ESMO Open</i> , 2020 , 5, e000801	6	1
245	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2020 , 14, 1179554920946693	1.8	3
244	Denosumab for cancer-related bone loss. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1261-1274	5.4	4
243	Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study. <i>Oncology</i> , 2020 , 98, 893-896	3.6	1
242	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 191-199.e6	3.8	10
241	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 121, 593-599	8.7	14
240	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. <i>Cancers</i> , 2019 , 11,	6.6	14
239	No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. <i>European Journal of Cancer Care</i> , 2019 , 28, e13112	2.4	4
238	New frontiers in the medical management of gastrointestinal stromal tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919841946	5.4	21
237	Early use of abiraterone and radium-223 in metastatic prostate cancer. <i>Lancet Oncology, The</i> , 2019 , 20, e228	21.7	5
236	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019 , 24, e327-e337	5.7	80
235	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 2019 , 7, 57		155
234	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019 , 111, 94-106	7.5	25
233	Role of SIRT-3, p-mTOR and HIF-1 α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
232	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 529.e1-529.e7	2.8	4
231	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, 237-247.e1	4.9	76
230	Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 422-431	6.1	19
229	Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. <i>Chemotherapy</i> , 2019 , 64, 105-109	3.2	5

228	Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019 , 18, 100252	4.5	13
227	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2365-2373	4.9	6
226	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , 2019 , 79, 1211-1220	4.2	14
225	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919877725	5.4	8
224	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019 , 2019, 7317964	4.5	5
223	Cabozantinib and apixaban: an hitherto unreported interaction. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 22	7.8	5
222	Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3508-3508	2.2	12
221	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16013-e16013	2.2	1
220	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS731-TPS731	2.2	6
219	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2559-2559	2.2	
218	Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3534-3534	2.2	
217	Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11591-11591	2.2	
216	Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11053-11053	2.2	
215	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3540-3540	2.2	
214	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4075-4075	2.2	
213	Immunotherapy discontinuation and outcome: A multicenter real-life experience.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14075-e14075	2.2	
212	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
211	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019 , 17, 376	8.5	16

210	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919890285	5.4	49
209	Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). <i>Radiologia Medica</i> , 2019 , 124, 34-49	6.5	45
208	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 343-350	13.4	134
207	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018 , 95, 1-7	3.6	5
206	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 240.e1-240.e11	2.8	13
205	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 125, 51-59	7	7
204	Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer. <i>Chemotherapy</i> , 2018 , 63, 83-89	3.2	5
203	Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 461-467	5.5	7
202	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
201	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 705-709	2.4	1
200	Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. <i>BMJ Supportive and Palliative Care</i> , 2018 , 8, 241-249	2.2	22
199	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 18887-18887	2.2	10
198	FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11556-11556	2.2	1
197	The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice. <i>Oncology Letters</i> , 2018 , 16, 7195-7203	2.6	2
196	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018 , 38, 5773-5782	2.3	10
195	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918794623	5.4	15
194	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000353	6	30
193	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018 , 104, 476-479	1.7	12

192	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 355-359.e1	3.3	22
191	HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. <i>Pathology and Oncology Research</i> , 2017 , 23, 55-61	2.6	10
190	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017 , 55, 71-82	14.4	36
189	Determinants of bone specific metastasis in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 59-66	7	14
188	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 115, 1-12	7	20
187	Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1872-1880	4	10
186	Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 43-51	7	26
185	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017 , 20, 825-833	7.6	24
184	Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. <i>European Journal of Cancer</i> , 2017 , 71, 80-94	7.5	45
183	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , 2017 , 86, 106-114	7.5	54
182	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017 , 7, 10597	4.9	11
181	Developing drugs in cancer-related bone pain. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 119, 66-74	7	11
180	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 118, 1-6	7	10
179	The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 120, 227-233	7	12
178	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. <i>British Journal of Cancer</i> , 2017 , 117, 340-346	8.7	16
177	Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. <i>Oncotarget</i> , 2017 , 8, 20113-20121	3.3	29
176	Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. <i>Oncotarget</i> , 2017 , 8, 59986-59990	3.3	10
175	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017 , 8, 56921-56931	3.3	41

174	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , 2017 , 8, 66699-66708	3.3	11
173	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017 , 8, 100708-100716	3.3	20
172	A phase 2 study of temozolomide in patients affected by pretreated metastatic colorectal cancer with MGMT promoter methylation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 629-629	2.2	
171	BMI as a risk factor for toxicities in patients with advanced soft tissue sarcoma treated with trabectedin.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e22517-e22517	2.2	
170	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11038-11038	2.2	
169	TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4601-TPS4601	2.2	
168	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15684-e15684	2.2	
167	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016 , 21, 600-7	5.7	20
166	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 106, 132-42	7	7
165	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , 2016 , 51, 54-62	14.4	19
164	RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	3
163	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. <i>Scientific Reports</i> , 2016 , 6, 24136	4.9	16
162	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
161	Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. <i>Journal of Clinical Oncology</i> , 2016 , 34, 436-42	2.2	106
160	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 254-63	7	1
159	M1-polarized macrophages as predictor of poor response to trabectedin treatment in myxoid liposarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e22537-e22537	2.2	1
158	Biological effects of cabozantinib on bone microenvironment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23004-e23004	2.2	1
157	TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC) liquid biopsy for biomarkers discovery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4584-TPS4584	2.2	1

156	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , 2016 , 7, 67142-67149	3.3	76
155	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016 , 7, 69412-69419	3.3	10
154	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016 , 7, 17932-44	3.3	26
153	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016 , 7, 19738-47	3.3	106
152	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10
151	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. <i>Oncotarget</i> , 2016 , 7, 29321-32	3.3	21
150	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 210-210	2.2	
149	Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A Real lifeRetrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 337-337	2.2	
148	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3629-TPS3629	2.3	
147	Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11062-11062	2.2	
146	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1219-38	4.1	33
145	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. <i>Eur Urol</i> 2015;68:542-3. <i>European Urology</i> , 2016 , 70, e69-70	10.2	
144	Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 925-35	4.1	43
143	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10	12.8	50
142	Tissue engineering and microRNAs: future perspectives in regenerative medicine. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1601-22	5.4	19
141	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 306-17	7	19
140	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015 , 41, 767-76	14.4	55
139	Emerging drugs for the treatment of bone metastasis. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 637-517	5	

138	Percutaneous Long Bone Cementoplasty for Palliation of Malignant Lesions of the Limbs: A Systematic Review. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 1563-72	2.7	37
137	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
136	Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. <i>BMC Cancer</i> , 2015 , 15, 87	4.8	27
135	Classic Kaposi Sarcoma: to treat or not to treat?. <i>BMC Research Notes</i> , 2015 , 8, 138	2.3	7
134	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015 , 368, 20-25	9.9	15
133	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 765-73	9.6	28
132	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S276-S304	12.7	179
131	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 50-9	7	11
130	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
129	Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. <i>Scientific Reports</i> , 2015 , 5, 12077	4.9	1
128	Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. <i>Breast Cancer Research</i> , 2015 , 17, 121	8.3	25
127	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 156	12.8	40
126	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015 , 75, 1329-38	4.2	16
125	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0136731	3.7	7
124	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. <i>Oncotarget</i> , 2015 , 6, 23323-41	3.3	55
123	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 81-90	7	45
122	Pazopanib and pancreatic toxicity: a case report. <i>BMC Research Notes</i> , 2015 , 8, 196	2.3	8
121	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015 , 1, FSO15	2.7	39

120	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 206-19	7	20
119	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 53	22.4	30
118	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
117	Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. <i>Cancer Treatment Reviews</i> , 2015 , 41, 136-43	14.4	65
116	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15594-e15594	2.2	1
115	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 412-412	2.2	3
114	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A Real-life study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 424-424	2.2	9
113	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , 2015 , 10, e0120427	3.7	8
112	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0133488	3.7	76
111	Deregulation of dicer and mir-155 expression in liposarcoma. <i>Oncotarget</i> , 2015 , 6, 10586-91	3.3	17
110	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. <i>Oncotarget</i> , 2015 , 6, 12520-8	3.3	41
109	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 32161-8	3.3	24
108	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12	3.3	27
107	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 313-313	2.2	
106	FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 372-372	2.2	
105	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 213-213	2.2	
104	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15126-e15126	2.2	
103	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22075-e22075	2.2	

102	Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15246-e15246	2.2	
101	Different Levels of Alkaline Phosphatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions. <i>Blood</i> , 2015 , 126, 5359-5359	2.2	
100	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 248-54	11.2	21
99	Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 113-21	4.4	13
98	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014 , 135, 763-73	7.5	33
97	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 221-31	11.2	41
96	Liquid biopsies in lung cancer: the new ambrosia of researchers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 539-46	11.2	95
95	Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view. <i>Clinical Colorectal Cancer</i> , 2014 , 13, e13-5	3.8	13
94	Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-D computed tomography volumetry. <i>Clinical Breast Cancer</i> , 2014 , 14, 365-70	3	11
93	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <i>Pharmacogenomics</i> , 2014 , 15, 1701-16	16	4
92	MicroRNAs and bone metastasis: a new challenge. <i>Molecules</i> , 2014 , 19, 10115-28	4.8	15
91	Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 208-17	7	25
90	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 321-31	9.6	21
89	Clinical Features of Male Breast Cancer and Multimodal Treatment: A Comment to Retrospective Survey Analysis at Italian Centers. <i>Tumori</i> , 2014 , 100, e169-e170	1.7	1
88	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10515-10515	2.2	1
87	Second-line treatment in patients with FOLFIRINOX-refractory pancreatic adenocarcinoma (PDAC): Doublets or single-agent chemotherapy?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15186-e15186	2.2	1
86	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 253-253	2.2	1
85	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 471-471	2.2	7

84	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15568-e15568	2.2	
83	The potential diagnostic role of procalcitonin for bacteremia in a large cohort of solid cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20664-e20664	2.2	
82	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15588-e15588 ^{2.2}	2.2	
81	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15563-e15563	2.2	
80	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10572-10572	2.2	
79	Bisphosphonates in Bone Metastatic Setting. <i>Cancer Metastasis - Biology and Treatment</i> , 2014 , 217-234		
78	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 421-421	2.2	
77	Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 92	12.8	66
76	Targeting Bone Metastases: New Drugs for New Targets. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2013 , 11, 103-112	2.5	1
75	Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 473-4	6.4	
74	Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. <i>Oncology</i> , 2013 , 85, 342-7	3.6	9
73	'Old' and 'new' drugs for the treatment of cancer pain. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 425-33	4	6
72	Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. <i>Lancet Oncology, The</i> , 2013 , 14, 663-70	21.7	138
71	Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?. <i>Future Oncology</i> , 2013 , 9, 1809-11	3.6	1
70	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , 2013 , 8, e83026	3.7	52
69	The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. <i>PLoS ONE</i> , 2013 , 8, e79658	3.7	20
68	Effect of cholesterol and triglyceride increases on time to progression in renal clear cell cancer patients treated with everolimus.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15528-e15528	2.2	
67	Natural history of malignant bone disease in gastric cancer: Final results of a multicenter bone metastasis survey.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4091-4091	2.2	

66	Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19084-e19084	2.2	1
65	RANK/RANKL pathway in cancer: Biological activity beyond bone?. <i>Journal of Bone Oncology</i> , 2012 , 1, 67-8	4.5	1
64	Evidence-based guidelines: Improving AGREEment on consistence evaluation. <i>Journal of Bone Oncology</i> , 2012 , 1, 30-4	4.5	
63	Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 56	22.4	33
62	Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. <i>Lancet Oncology, The</i> , 2012 , 13, 1020-4	21.7	87
61	Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1491-500	4.6	46
60	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1283-8	3.5	7
59	Premetastatic niche: ready for new therapeutic interventions?. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 2, S119-29	6.4	30
58	A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. <i>Oncology</i> , 2012 , 82, 75-82	3.6	7
57	ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9005-9005	2.2	7
56	The role of bone microenvironment, vitamin D and calcium. <i>Recent Results in Cancer Research</i> , 2012 , 192, 33-64	1.5	9
55	Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab. <i>Recent Results in Cancer Research</i> , 2012 , 192, 171-85	1.5	4
54	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. <i>Oncology Reports</i> , 2011 , 25, 1545-8	3.5	4
53	Receptor activator of NF- κ B (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. <i>PLoS ONE</i> , 2011 , 6, e19234	3.7	136
52	Expression pattern of receptor activator of NF κ B (RANK) in a series of primary solid tumors and related bone metastases. <i>Journal of Cellular Physiology</i> , 2011 , 226, 780-4	7	95
51	Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). <i>Current Cancer Drug Targets</i> , 2011 , 11, 123-9	2.8	36
50	Role of GPR30 in testicular germ cell tumors: a potential new anticancer target. <i>Cancer Biology and Therapy</i> , 2011 , 11, 773-5	4.6	4
49	New targets, new drugs for metastatic bone pain: a new philosophy. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 403-5	3.7	13

48	Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. <i>Current Cancer Drug Targets</i> , 2010 , 10, 46-54	2.8	23
47	Aprepitant for erlotinib-induced pruritus. <i>New England Journal of Medicine</i> , 2010 , 363, 397-8	59.2	71
46	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , 2010 , 11, 753-62	21.7	1653
45	Aprepitant against pruritus in patients with solid tumours. <i>Supportive Care in Cancer</i> , 2010 , 18, 1229-30	3.9	47
44	Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. <i>Journal of Cellular Physiology</i> , 2010 , 223, 384-8	7	30
43	KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 565-77	5.4	8
42	Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. <i>Cancer</i> , 2009 , 115, 4849-56	6.4	27
41	In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 31-8	7.4	88
40	Are bisphosphonates the suitable anticancer drugs for the elderly?. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 69, 83-94	7	17
39	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 86-90	1.6	2
38	Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1427-34	2.2	113
37	Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 875-83	5.4	37
36	Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 304-5		
35	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. <i>Oncologist</i> , 2008 , 13, 1270-5	5.7	197
34	Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. <i>Supportive Care in Cancer</i> , 2008 , 16, 209-14	3.9	15
33	Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 711-21		71
32	R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. <i>Journal of Cellular Physiology</i> , 2007 , 211, 533-43	7	55
31	Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 613-20	3.5	17

30	Bisphosphonates: from preclinical evidence to survival data in the oncologic setting. <i>Oncology Reviews</i> , 2007 , 1, 141-151	4.3	
29	Zoledronic Acid and Angiogenesis. <i>Clinical Cancer Research</i> , 2007 , 13, 6850.2-6851	12.9	1
28	Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 1571-86	6.4	10
27	Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. <i>Pharmacogenomics</i> , 2007 , 8, 319-27	2.6	33
26	Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. <i>Clinical Cancer Research</i> , 2007 , 13, 4482-6	12.9	151
25	Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. <i>BMC Cancer</i> , 2006 , 6, 42	4.8	3
24	Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?. <i>Women's Health</i> , 2006 , 2, 1-3	3	1
23	Taxanes in adjuvant chemotherapy for early breast cancer. <i>Women's Health</i> , 2006 , 2, 323-5	3	
22	New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1957; author reply 1957-8	2.2	25
21	Emerging anti-cancer molecular mechanisms of aminobisphosphonates. <i>Endocrine-Related Cancer</i> , 2006 , 13, 7-26	5.7	109
20	Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 325-38		47
19	Zoledronic acid in the management of metastatic bone disease. <i>Expert Opinion on Biological Therapy</i> , 2006 , 6, 1333-48	5.4	27
18	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 665-83	3.7	1
17	Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006 , 1, 383-96	2.6	23
16	An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer. <i>In Vivo</i> , 2006 , 20, 165-8	2.3	8
15	Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. <i>Oncology Reports</i> , 2006 , 15, 1351-7	3.5	38
14	Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. <i>Oncology</i> , 2005 , 69, 27-34	3.6	23
13	Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. <i>Journal of Interferon and Cytokine Research</i> , 2005 , 25, 144-51	3.5	106

12	A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study. <i>Anticancer Research</i> , 2005 , 25, 669-74	2.3	4
11	Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. <i>Oncology</i> , 2004 , 67, 135-42	3.6	15
10	Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. <i>Medical Oncology</i> , 2004 , 21, 59-66	3.7	13
9	Predictive factors for response to chemotherapy in colorectal cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 52, 45-60	7	8
8	Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. <i>BioDrugs</i> , 2004 , 18, 269-78	7.9	44
7	Thrombophilic Genetic Mutations Have No Impact in the Pathogenesis of Thromboembolism in Gastro-Intestinal Cancer Patients.. <i>Blood</i> , 2004 , 104, 3518-3518	2.2	
6	Cytokines Behaviour in Multiple Myeloma during Zoledronic Acid Treatment.. <i>Blood</i> , 2004 , 104, 4913-4913	13.2	
5	Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. <i>Journal of Interferon and Cytokine Research</i> , 2003 , 23, 649-54	3.5	105
4	Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. <i>Clinical Cancer Research</i> , 2003 , 9, 2893-7	12.9	221
3	Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 3215; author reply 3216	12.9	4
2	S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. <i>Anticancer Research</i> , 2003 , 23, 5173-9	2.3	20
1	Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. <i>Clinical Cancer Research</i> , 2002 , 8, 1080-4	12.9	194